Guardion Health Sciences reports FY22 EPS ($14.15) vs ($52.23) last year

Reports FY22 revenue $11.05M vs $7.23M last year. Bret Scholtes, Guardion’s President and Chief Executive Officer, commented, "Over the course of 2022 we diligently worked to build a stronger clinical nutrition company despite a challenging macroenvironment that included external economic pressures, volatile capital markets, a changing consumer marketplace and complex supply chain issues. Compared to our results for 2021, we have increased sales and gross profit, while also reducing major cost categories and streamlining operations. We plan to continue to evaluate our costs in 2023 in order to further improve our operating efficiencies."